A phase IV randomised, open-label pilot study to evaluate switching from protease-inhibitor based regimen to Bictegravir/Emtricitabine/Tenofovir Alafenamide single tablet regimen in Integrase inhibitor-naïve, virologically suppressed HIV-1 infected adults harbouring drug resistance mutations (PIBIK study): study protocol for a randomised trial.
Saved in:
| Title: | A phase IV randomised, open-label pilot study to evaluate switching from protease-inhibitor based regimen to Bictegravir/Emtricitabine/Tenofovir Alafenamide single tablet regimen in Integrase inhibitor-naïve, virologically suppressed HIV-1 infected adults harbouring drug resistance mutations (PIBIK study): study protocol for a randomised trial. |
|---|---|
| Authors: | Iwuji, Collins C.1,2 (AUTHOR) c.iwuji@bsms.ac.uk, Churchill, Duncan2 (AUTHOR), Bremner, Stephen3 (AUTHOR), Perry, Nicky2 (AUTHOR), To, Ye4 (AUTHOR), Lambert, Debbie4 (AUTHOR), Bruce, Chloe4 (AUTHOR), Waters, Laura5 (AUTHOR), Orkin, Chloe6,7 (AUTHOR), Geretti, Anna Maria8 (AUTHOR) |
| Source: | BMC Infectious Diseases. 7/20/2020, Vol. 20 Issue 1, p1-12. 12p. 1 Diagram, 3 Charts. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
